Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_assertion type Assertion NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_head.
- NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_assertion description "[To compare the performance characteristics of prostate cancer risk factors such as total prostate-specific antigen (tPSA), percentage free PSA (%fPSA), PSA velocity (PSAV) and urinary prostate cancer gene 3 (PCA3) at first, second and ? third repeat biopsy session.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_provenance.
- NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_assertion evidence source_evidence_literature NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_provenance.
- NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_assertion SIO_000772 21939492 NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_provenance.
- NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_assertion wasDerivedFrom befree-2016 NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_provenance.
- NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_assertion wasGeneratedBy ECO_0000203 NP925662.RAPQytVgaFUUKkglfO2EVyMaL7FHXq9-Xv-ug3XtmOtTQ130_provenance.